Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Cash from Investing Activities (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Cash from Investing Activities for 9 consecutive years, with $18.7 million as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities fell 78.62% to $18.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45.0 million through Dec 2025, down 79.4% year-over-year, with the annual reading at $45.0 million for FY2025, 79.4% down from the prior year.
  • Cash from Investing Activities hit $18.7 million in Q4 2025 for Sutro Biopharma, down from $40.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $147.3 million in Q3 2024 to a low of -$121.7 million in Q1 2021.
  • Historically, Cash from Investing Activities has averaged $6.4 million across 5 years, with a median of $12.3 million in 2021.
  • Biggest YoY gain for Cash from Investing Activities was 715.44% in 2022; the steepest drop was 3380.69% in 2022.
  • Year by year, Cash from Investing Activities stood at $20.8 million in 2021, then plummeted by 282.29% to -$37.9 million in 2022, then skyrocketed by 37.93% to -$23.5 million in 2023, then skyrocketed by 472.08% to $87.5 million in 2024, then plummeted by 78.62% to $18.7 million in 2025.
  • Business Quant data shows Cash from Investing Activities for STRO at $18.7 million in Q4 2025, $40.0 million in Q3 2025, and $2.6 million in Q2 2025.